173 related articles for article (PubMed ID: 35286913)
1. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
4. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
Ding Y; Liu Y; Dou C; Guo S
J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
[TBL] [Abstract][Full Text] [Related]
7. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
Zhang S; Yin Y; Xiong H; Wang J; Liu H; Lu J; Zhang Q; Zhang L; Zhong J; Nie J; Lei K; Wang H; Yang S; Yao H; Wu H; Yu D; Ji X; Zhang H; Wu F; Xie W; Li W; Yao W; Zhong D; Sun H; Sun T; Guo Z; Wang R; Guo Y; Yu Z; Li D; Jin H; Song H; Chen X; Ma W; Hu Z; Liu D; Guo Y; Tang J; Jiang Z
JAMA Oncol; 2024 Apr; 10(4):448-455. PubMed ID: 38329745
[TBL] [Abstract][Full Text] [Related]
11. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
[TBL] [Abstract][Full Text] [Related]
12. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.
Chen H; Chen W; Yuan F; Guo Q; Zhang X; Wang C; Li X
Front Pharmacol; 2022; 13():821944. PubMed ID: 35140619
[No Abstract] [Full Text] [Related]
14. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
16. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
Expert Opin Biol Ther; 2024 Feb; ():1-9. PubMed ID: 38349618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
